Cardiac MRI in diagnosis and management

Jonathan Kahan, Juan Gaztanaga, Mario J. Garcia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cardiac magnetic resonance imaging (CMR) is an essential tool in the diagnosis, risk stratification and treatment of patients with hypertrophic cardiomyopathy (HCM). CMR works by manipulating protons found in myocytes and contrast agents such as Gadolinium, using magnetic pull to create and then detect energy differences and thus obtain images. CMR is ideal for detecting the location and extent of hypertrophy, presence or absence of membranes, the distribution of fibrosis and the anatomy and physiology of the mitral valve, all of which are crucial for diagnosis of HCM, which can be missed on standard echocardiography. This is especially true for hard to see areas of the heart such as the apical area as well as atypical presentations such as focal segmental hypertrophy or mass-like HCM. Additionally, extremely accurate assessments of the left ventricular volumes, mass and function are prognostic as well as diagnostic. Magnetic resonance tagging and delayed-enhancement with Gadolinium allow for strain and perfusion analysis, further increasing the utility of CMR to detect regional function and cardiac microvascular ischemia, of which HCM patients are particularly susceptible. Delayed enhancement distribution and extent may also impact risk stratification for sudden cardiac death. Limitations of CMR include assessment of the left ventricular outflow tract gradient and highly mobile structures on the mitral valve, although newer protocols and improved technology may be able to compensate for these deficits in the future.

Original languageEnglish (US)
Title of host publicationHypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald
PublisherSpringer-Verlag London Ltd
Pages55-75
Number of pages21
ISBN (Print)9781447149569, 9781447149552
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hypertrophic Cardiomyopathy
Magnetic Resonance Imaging
Gadolinium
Mitral Valve
Hypertrophy
Sudden Cardiac Death
Muscle Cells
Contrast Media
Echocardiography
Protons
Anatomy
Fibrosis
Magnetic Resonance Spectroscopy
Ischemia
Perfusion
Technology
Membranes
Therapeutics

Keywords

  • Cardiac magnetic resonance imaging
  • Fibrosis
  • Late gadolinium enhancement
  • Microvascular ischemia
  • MRI safety
  • Sudden cardiac death risk factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kahan, J., Gaztanaga, J., & Garcia, M. J. (2015). Cardiac MRI in diagnosis and management. In Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald (pp. 55-75). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4956-9_5

Cardiac MRI in diagnosis and management. / Kahan, Jonathan; Gaztanaga, Juan; Garcia, Mario J.

Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd, 2015. p. 55-75.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kahan, J, Gaztanaga, J & Garcia, MJ 2015, Cardiac MRI in diagnosis and management. in Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd, pp. 55-75. https://doi.org/10.1007/978-1-4471-4956-9_5
Kahan J, Gaztanaga J, Garcia MJ. Cardiac MRI in diagnosis and management. In Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd. 2015. p. 55-75 https://doi.org/10.1007/978-1-4471-4956-9_5
Kahan, Jonathan ; Gaztanaga, Juan ; Garcia, Mario J. / Cardiac MRI in diagnosis and management. Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd, 2015. pp. 55-75
@inbook{e6e707fcfce64e5d833b4c465fca4d00,
title = "Cardiac MRI in diagnosis and management",
abstract = "Cardiac magnetic resonance imaging (CMR) is an essential tool in the diagnosis, risk stratification and treatment of patients with hypertrophic cardiomyopathy (HCM). CMR works by manipulating protons found in myocytes and contrast agents such as Gadolinium, using magnetic pull to create and then detect energy differences and thus obtain images. CMR is ideal for detecting the location and extent of hypertrophy, presence or absence of membranes, the distribution of fibrosis and the anatomy and physiology of the mitral valve, all of which are crucial for diagnosis of HCM, which can be missed on standard echocardiography. This is especially true for hard to see areas of the heart such as the apical area as well as atypical presentations such as focal segmental hypertrophy or mass-like HCM. Additionally, extremely accurate assessments of the left ventricular volumes, mass and function are prognostic as well as diagnostic. Magnetic resonance tagging and delayed-enhancement with Gadolinium allow for strain and perfusion analysis, further increasing the utility of CMR to detect regional function and cardiac microvascular ischemia, of which HCM patients are particularly susceptible. Delayed enhancement distribution and extent may also impact risk stratification for sudden cardiac death. Limitations of CMR include assessment of the left ventricular outflow tract gradient and highly mobile structures on the mitral valve, although newer protocols and improved technology may be able to compensate for these deficits in the future.",
keywords = "Cardiac magnetic resonance imaging, Fibrosis, Late gadolinium enhancement, Microvascular ischemia, MRI safety, Sudden cardiac death risk factor",
author = "Jonathan Kahan and Juan Gaztanaga and Garcia, {Mario J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4471-4956-9_5",
language = "English (US)",
isbn = "9781447149569",
pages = "55--75",
booktitle = "Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Cardiac MRI in diagnosis and management

AU - Kahan, Jonathan

AU - Gaztanaga, Juan

AU - Garcia, Mario J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cardiac magnetic resonance imaging (CMR) is an essential tool in the diagnosis, risk stratification and treatment of patients with hypertrophic cardiomyopathy (HCM). CMR works by manipulating protons found in myocytes and contrast agents such as Gadolinium, using magnetic pull to create and then detect energy differences and thus obtain images. CMR is ideal for detecting the location and extent of hypertrophy, presence or absence of membranes, the distribution of fibrosis and the anatomy and physiology of the mitral valve, all of which are crucial for diagnosis of HCM, which can be missed on standard echocardiography. This is especially true for hard to see areas of the heart such as the apical area as well as atypical presentations such as focal segmental hypertrophy or mass-like HCM. Additionally, extremely accurate assessments of the left ventricular volumes, mass and function are prognostic as well as diagnostic. Magnetic resonance tagging and delayed-enhancement with Gadolinium allow for strain and perfusion analysis, further increasing the utility of CMR to detect regional function and cardiac microvascular ischemia, of which HCM patients are particularly susceptible. Delayed enhancement distribution and extent may also impact risk stratification for sudden cardiac death. Limitations of CMR include assessment of the left ventricular outflow tract gradient and highly mobile structures on the mitral valve, although newer protocols and improved technology may be able to compensate for these deficits in the future.

AB - Cardiac magnetic resonance imaging (CMR) is an essential tool in the diagnosis, risk stratification and treatment of patients with hypertrophic cardiomyopathy (HCM). CMR works by manipulating protons found in myocytes and contrast agents such as Gadolinium, using magnetic pull to create and then detect energy differences and thus obtain images. CMR is ideal for detecting the location and extent of hypertrophy, presence or absence of membranes, the distribution of fibrosis and the anatomy and physiology of the mitral valve, all of which are crucial for diagnosis of HCM, which can be missed on standard echocardiography. This is especially true for hard to see areas of the heart such as the apical area as well as atypical presentations such as focal segmental hypertrophy or mass-like HCM. Additionally, extremely accurate assessments of the left ventricular volumes, mass and function are prognostic as well as diagnostic. Magnetic resonance tagging and delayed-enhancement with Gadolinium allow for strain and perfusion analysis, further increasing the utility of CMR to detect regional function and cardiac microvascular ischemia, of which HCM patients are particularly susceptible. Delayed enhancement distribution and extent may also impact risk stratification for sudden cardiac death. Limitations of CMR include assessment of the left ventricular outflow tract gradient and highly mobile structures on the mitral valve, although newer protocols and improved technology may be able to compensate for these deficits in the future.

KW - Cardiac magnetic resonance imaging

KW - Fibrosis

KW - Late gadolinium enhancement

KW - Microvascular ischemia

KW - MRI safety

KW - Sudden cardiac death risk factor

UR - http://www.scopus.com/inward/record.url?scp=84948120349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948120349&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4956-9_5

DO - 10.1007/978-1-4471-4956-9_5

M3 - Chapter

AN - SCOPUS:84948120349

SN - 9781447149569

SN - 9781447149552

SP - 55

EP - 75

BT - Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald

PB - Springer-Verlag London Ltd

ER -